This document summarizes a sales meeting for Pharco B International CO., a pharmaceutical company. It discusses Pharco B's profile, products for dental infections and skin/soft tissue infections. Key products highlighted include Ultramox (amoxicillin/clavulanic acid) and Ceforan (cefotaxime). Ultramox is indicated for dental infections like abscesses and stomatitis. Ceforan is highlighted as being safe for neonatal use. The document provides details on the companies, products, indications, and dosing.

1. Pharco B Group Meeting
Pharco B International CO.
Medical Rep. Name
PBI Medical Rep.
Line 3 – Sales Department, PBI.

2. • Pharco B company profile.
• Dental Infections/Indications.
• Products overview.
Agenda
PBI I Marketing Department 2

3. Pharco Corporation
• Pharco Corporation is the largest manufacturer of pharmaceuticals in the MENA region, focused on research, formulation,
manufacturing and commercialization of pharmaceutical products.
• Eight healthcare companies are operating in the pharmaceutical field for development, manufacturing, marketing, distributing and
exporting of a comprehensive array of generics and branded generic drugs under the name of Pharco, along with a rising number of
licensed pharmaceutical products.
• Ranking as the LEADER in the Egyptian pharmaceutical market.
• Pharco also exports to 53 countries around the world.
PBI I Marketing Department 3

4. 600+ PHARMACEUTICAL PRODUCT
PBI I Marketing Department 4

5. 2.5 MILLION PACK
PRODUCED DAILY
PBI I Marketing Department 5

6. 700+
PATIENT/MINUTE
PBI I Marketing Department 6

7. 4+ MILLION CURED
FROM HEPATITIS C
PBI I Marketing Department 7

8. About Pharco B International
• A private Egyptian shareholding
company based in Alexandria,
Egypt.
• Operating under the umbrella
of Pharco Corporation
• Founded in 2008 as a dedicated
unit for Cephalosporin and its
derivatives.
• Manufacturing for both local
and export markets
PBI I Marketing Department 8

9. Evolution of Pharco B International
• 2008 was the first dedicated facility
for production of Cephalosporin.
• Non-Sterile Solid Forms Line
• Sterile Vials Line
• 2010 one product line for Water For
Injection.
• 2012 Two product lines for Small
Volume Parenterals with two sterile
areas.
• 2013 Large Volume Parenterals line.
• 2020 Carbapenems Units.
PBI I Marketing Department 9

10. Research & Development
• Patient-centric approach to develop generic
products that comply with strict international
standards at reasonable affordable cost.
• Pipeline products ensure local and regional
leadership in anti-infective and sterile
therapeutics.
• Integrated development approach
considering different product dimensions;
• Formulation
• Analysis
• Packaging
• Multi-disciplinary team of scientists and
pharmacists.
• State of art infrastructure to meet the
directorate functions;
PBI I Marketing Department 10

11. Certifications
We comply with the most advanced international production
norms and regulations. We are dedicated to demonstrate and
operate in a quality based environment that complies with
international regulations.
PBI I Marketing Department 11

12. PBI I Marketing Department 12

13. Indications of antibiotics in dental infections:
https://www.hindawi.com/journals/ijd/2021/6667624/
• It forms at the root tip.
Periapical
Abscess
• It forms in the space between
the gum and tooth.
Gingival Abscess
• It forms in a periodontal
pocket.
Periodontal
Abscess
• It forms around impacted or
partially erupted tooth.
Pericoronal
Abscess
Types of Dental Abscess
PBI I Marketing Department 13

14. Pathogens in Dental Infections:
• The acute dental abscess is usually
polymicrobial comprising facultative
anaerobes, such as viridians group
streptococci and the Streptococcus
anginosus group, with predominantly
strict anaerobes, such as anaerobic
cocci, Prevotella and Fusobacterium
Species.
PBI I Marketing Department 14

15. Skin and Soft Tissue Infections:
• Result from microbial invasion of the skin and its supporting structures.
• Management is determined by the severity and the location of the infection
and by the patient co-morbidities
• Infections can be classified as:
Simple and complicated
PBI I Marketing Department 15

16. Periapical Abscess
• Is a collection of pus at the root of a
tooth.
Usually caused by an infection that has
spread from a tooth to the surrounding
tissues .
The body attacks an infection with a
large numbers of
White blood cells.
https://www.msdmanuals.com/home/mouth-and-dental-disorders/tooth-disorders/periapical-abscess
PBI I Marketing Department 16

17. Gingival Abscess:
• Caused by bacterial infection due to tooth decay,
• Rough brushing , broken teeth , food stuck in the
• Gum line or when bleeding occurs in the gum
line.
Traumatic injury or any excessive orthodontic force
on
The teeth can also cause gingival abscess
It looks like small red ball pushing out of the
swollen gum.
https://www.healthline.com/health/gum-abscess PBI I Marketing Department 17

18. Stomatitis
General term for an inflamed and sore
mouth can disrupt a person’s ability to eat,
talk, or sleep.
- It can occur anywhere in the mouth,
including the inside of the cheeks, gums,
tongue, lips, and palate.
https://www.webmd.com/oral-health/guide/stomatitis-causes-treatment
PBI I Marketing Department 18

19. are indicated for the treatment of infections caused by organisms:
 Dental Infections
 Abscess : Tooth abscess - Root abscess
 Stomatitis
 Stomatitis : ulcerative - vesicular
 Cellulitis and abscess of mouth
 Oral mucositis : Ulcerative mucositis (oral or oropharyngeal)
PBI I Marketing Department 19

20. PBI I Marketing Department 20

21. PBI I Marketing Department 21

22. PBI I Marketing Department 22

23. PBI I Marketing Department 23

24. ULTRAMOX 1 gm (7:1)
Each film coated tablet contains:
• Amoxicillin trihydrate equivalent to 875 mg Amoxicillin.
• Potassium clavulanate equivalent to 125 mg Clavulanic acid.
COMPOSITION:
PBI I Marketing Department 24

25. ULTRAMOX 625 mg (4:1)
Each film coated tablet contains:
• Amoxicillin trihydrate equivalent to 500 mg Amoxicillin.
• Potassium clavulanate equivalent to 125 mg Clavulanic acid.
COMPOSITION:
PBI I Marketing Department 25

26. Mode of Action:
• ULTRAMOX, through its synergistically acting components, irreversibly inhibits bacterial
cell wall synthesis resulting in rapid and complete eradication of susceptible bacteria.
PBI I Marketing Department 26

27. DOSAGE:
Adults and Children over 12 years
 Mild to moderate infections 625 mg given twice daily or three times daily, or 1 gm given twice daily.
 Severe infections (including chronic and recurrent urinary tract infections and those of the lower respiratory tract) 625 mg given three
times daily, or 1 gm given three times daily.
PBI I Marketing Department 27
Dosage in renal impairment
N.B.: ULTRAMOX Tablets 1 gm should only be used in adult patients with a
glomerular filtration rate of > 30 ml/min.
Mild Impairment
(Creatinine clearance
> 30 ml / min.)
Moderate Impairment
(Creatinine clearance
10 - 30 ml / min.)
Severe Impairment
(Creatinine clearance
< 10 ml / min.)
ADULT No change in dosage. 625 mg tablet b.i.d. 625 mg tablet o.d.

28. PBI I Marketing Department 28
Dosage in hepatic impairment
The dose is taken with caution, monitoring hepatic function at regular intervals is required.
Method of Administration
• For ULTRAMOX Tablets 625 mg & 1 gm: To minimize potential gastrointestinal intolerance,
administer at the start of a meal.
PREGNANCY & LACTATION
ULTRAMOX is category B in pregnancy (Safe). ULTRAMOX may be administered during the period of lactation.

30. PACK & PRICE:
• 625 mg tablets: A carton box containing 12 tablets in 2 Alu/PVC blisters, each of 6 film coated
tablets = 37.75 L.E.
• 1 gm tablets: A carton box containing 12 tablets in 2 Alu/PVC blisters, each of 6 film coated tablets
= 46.25 L.E.
PBI I Marketing Department 30

31. PBI I Marketing Department 31

32. 32

33. Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs)
which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls,
thus inhibiting cell wall biosynthesis.
PBI I Marketing Department 33

34. Metabolism : Partially hepatic to active metabolite
Desacetylcefotaxime
PHARMACOKINETICS
PBI I Marketing Department 34

35. Ceforan (cefotaxime) is safe with Neonates because it is not highly bound
to plasma protein and doesn’t cause displacement to bilirubin as
ceftriaxone and it is mainly excreted via urine.
• No calcium interaction.
• Compatible with Ringer solution
• No dose adjustment with hepatic patient.
• Safe with Jaundiced new born, premature babies or babies with
Hypoalbuminemia.
• Low rates of complications & superinfections with children hospitalized
for serious infections.
Safety
PBI I Marketing Department 35

36. DOSAGE:
The following doses are recommended:
• Neonates (up to 7 days):
50 mg / kg / day, in equally divided doses every 12 hours.
• Neonates (7 days to 1 month):
50 mg / kg / day, in equally divided doses every 8 hours.
• Infants and children (up to 12 years):
150 - 200 mg/kg/day, in equally divided doses every 6–8 hours.
• In bacterial meningitis (for neonates, infants and children):
200 mg/kg/day in equally divided doses every 6 hours.
N.B Ceforan dose adjustment is required with neonates and renal impairment
(no dose adjustment with hepatic or elder patients)
PBI I Marketing Department 36

37. Ceforan (cefotaxime) is safe with Neonates because it is not highly
bound to plasma protein and doesn’t cause displacement to bilirubin as
ceftriaxone and it is mainly excreted via urine.
• No calcium interaction.
• Compatible with Ringer solution
• No dose adjustment with hepatic patient.
• Safe with Jaundiced new born, premature babies or babies with
Hypoalbuminemia.
• Low rates of complications & superinfections with children hospitalized
for serious infections.
Safety
PBI I Marketing Department 37

38. PBI I Marketing Department 38

39. 39

40. "Your Health. Our Mission."
PBI I Marketing Department 40